

# Double Trouble: A Case of Synchronous Breast and Renal Malignancies Associated with ATM Gene Mutation in a 41-Year-Old Filipino Female

Mary Neil T. Castillon MD<sup>1\*</sup>, Dawn Marie Dayot MD<sup>2</sup>, Mark Francis Claparols MD<sup>3</sup>, Julian Salvador Vinco MD<sup>4</sup> and Norman Cabaya MD<sup>5</sup>

<sup>1</sup> Internal Medicine, Resident in Training, Dr. Pablo O. Torre Memorial Hospital, Philippines.

<sup>2</sup> General Surgery, Resident in Training, Dr. Pablo O. Torre Memorial Hospital, Philippines.

<sup>3</sup> Breast Surgeon, Dr. Pablo O. Torre Memorial Hospital, Philippines.

<sup>4</sup> Urologist, Dr. Pablo O. Torre Memorial Hospital, Philippines.

<sup>5</sup> Medical Oncologist, Dr. Pablo O. Torre Memorial Hospital, Philippines.

**\*Corresponding Author:** Mary Neil T. Castillon MD, Internal Medicine, Resident in Training, Dr. Pablo O. Torre Memorial Hospital, Philippines.

DOI: <https://doi.org/10.58624/SVOAMR.2024.02.016>

**Received:** March 18, 2024 **Published:** August 12, 2024

## Abstract

**Introduction:** While renal cell carcinoma is the most common malignancy of the kidneys, and breast cancer is the leading type of malignancy in females, simultaneous diagnosis of both these malignancies in a patient is rare. In literature search, synchronous breast and renal malignancies were mostly presented in case reports due to its uncommon presentation.

**Case Report:** We report a case of a 41-year old Filipino female who initially complained of a right breast mass with nipple discharges. Breast ultrasound showed an irregular hypoechoic mass at the upper outer quadrant of the right breast measuring 7cm with equivocal/indeterminate features. Core needle biopsy was done revealing invasive mammary carcinoma, no special type, Black's Nuclear Grade 2, Luminal A ER/PR(+) Her2Neu(-). Upon metastatic work-up, an incidental finding of a large left renal mass on ultrasonography was seen and confirmed by whole abdominal computed tomography scan measuring 10.6x7.7x8cm. No urinary tract symptoms were experienced by the patient. Patient eventually had full course sequential neoadjuvant chemotherapy (4 cycles Doxorubicin/Cyclophosphamide and 4 cycles Docetaxel) then underwent total mastectomy with axillary lymph node dissection (ALND) followed by left radical nephrectomy in a single setting. Final histopathology report revealed Invasive Mammary Carcinoma PST IIIA (T2N2M0) no special type, Nottingham histologic Grade 3 and conventional Renal Clear Cell Carcinoma St II (T2aN0M0), Fuhrman Nuclear Grade 2. Genetic Testing was done with mutation in ATM gene.

**Conclusion:** The importance of holistic treatment in cancer patients cannot be over-emphasized. Complete history, physical examination and proper work up at the onset is of paramount importance in identification of possible synchronous malignancies, which may be treated simultaneously with curative intent.

**Keywords:** Breast Cancer, Renal Cell Carcinoma, Synchronous malignancy, Multiple primary malignancy

## Introduction

Despite the increasing number of cases of multiple primary malignancies, synchronous breast and renal cancer remain rare. Synchronous malignancies are malignant tumors occurring at the same time or within six months of diagnosis of the first tumor<sup>1</sup>. The identified tumors must present a definite picture of malignancy, each should be distinct, and the probability of one being a metastasis should be ruled out.


In the Philippines, breast cancer remains the leading type of malignancy in females<sup>2</sup>. On the other hand, renal cell carcinoma is the most common tumor of the kidney. When taken individually, these two disease entities are common. However, renal and breast cancer occurring together in a patient is a rare disease entity. Most studies of synchronous breast and renal cancer were described in case reports or small series. Approach, treatment and outcomes of concurrent renal and breast cancer are still uncertain due to the rarity of the disease and limited reports in the literature.

We report a case of a 41-year old female who presented with a right breast mass with findings of invasive mammary carcinoma on core needle biopsy with an incidental finding of a large left renal mass on whole abdomen ultrasound and computed tomography. Patient underwent right total mastectomy with axillary lymph node dissection (ALND) and left radical nephrectomy. Final histopathologic report of the left renal mass revealed renal clear cell carcinoma.

## Case Report

A 41-year old G4P4(4004), 5 months post-partum, breast feeding mother noted a palpable breast mass at the upper outer quadrant of her right breast. A month after, she noted progressive growth of the mass associated with breast discomfort and serosanguinous discharges from her right nipple. Patient then consulted with her Obstetrician-Gynecologist. Initial breast ultrasound was requested revealing multiple lesions seen from the 9 o'clock position all the way to the two o'clock position of the upper outer quadrant of the right breast, the largest measuring 4.1x3cm, some with benign sonographic characteristics and some are categorized as equivocal/indeterminate. Ultrasound of the contralateral left breast was unremarkable. She was then referred to a breast surgeon for further management. The patient has no known co-morbidities, a non-smoker, non-alcoholic beverage drinker with no history of illicit drug use. There is a family history of hypertension on both maternal and paternal side and type 2 diabetes on the maternal side. However, no family history of malignancy was reported in her 1<sup>st</sup> and 2<sup>nd</sup> degree relatives. Oral contraceptive use for 1 month was documented years prior.

Upon examination, a breast mass was noted at the upper outer quadrant of the right breast, fixed, hard, approximately more than 5cms almost occupying the whole nipple areolar complex with sanguinous discharges from the nipple. No skin changes or ulcerations were noted. An accessory breast was palpated at the right axilla with multiple enlarged fixed matted nodes. Clinical examination on the contralateral left breast and axilla were unremarkable. No palpable mass or nodes noted. Bedside ultrasound was done showing a 7cm irregular hypoechoic mass at the upper outer quadrant of the right breast with equivocal/indeterminate features (Figure 1).




**Figure 1:** Ultrasound of right breast mass prior to neoadjuvant chemotherapy showing a 7cm irregular hypoechoic mass at the upper outer quadrant of the right breast.

Core needle biopsy of the right breast mass was done revealing invasive mammary carcinoma Stage cIIIA (T3N2M0), no special type, Black's Nuclear Grade 2, hormone receptor status Luminal A ER/PR(+) Her2Neu(-). Fine needle aspiration biopsy of the right axillary nodes showed reactive lymphadenitis.


On metastatic workup, whole abdomen ultrasound showed an incidental finding of a large left renal mass. The patient had no associated urinary tract symptoms. Abdominal exam was also unremarkable with no palpable mass. Triphasic contrast enhanced computed tomography scan of the whole abdomen revealed a 10.6 x 7.7 x 8 cm well-circumscribed heterogenous left renal mass confined within the capsule extending to the central sinus and compressing the collecting system. Serum creatinine (0.62mg/dL) and other laboratories were normal.

Full course sequential neoadjuvant chemotherapy with 4 cycles of Cyclophosphamide + Doxycycline every 21 days followed by 4 cycles of Docetaxel every 21 days was done after referral to a medical oncologist. Partial response to therapy was noted (Figure 2).

Interval contrast enhanced computed tomography scan of the whole abdomen was done 2 months after showing no significant interval change in size of the renal mass 10.0 x 7.8 x 7.5 cm (previously 10.6 x 7.7 x 8 cm). (Figure 3)



**Figure 2:** Ultrasound of right breast mass during Neoadjuvant Chemotherapy showing a decrease in the size of the mass and partial response to therapy.



**Figure 3:** Oral and triphasic intravenous contrast enhanced axial CT image of the whole abdomen showing a well-circumscribed, heterogeneously enhancing left renal mass measuring 10x7.8x7.5cm.


Patient was scheduled for right total mastectomy with axillary lymph node dissection and left radical nephrectomy in one setting. She underwent surgery with no complications. Preoperatively, patient was given options for contralateral risk reducing surgery of the left breast but given the added operative time and risks, the patient did not consent.

Final histopathologic report showed right breast tissue post neoadjuvant chemotherapy with partial pathologic response, invasive mammary carcinoma pStIIIA(T2N2M0), no special type, tumor size 4.6cm in widest dimension, Nottingham histologic Grade 3 with peritumoral lymphovascular space invasion. Nipple and basal margin were negative for tumor involvement. 11 of the 32 axillary lymph nodes were positive for metastatic carcinoma (Figure 4). Left kidney biopsy revealed conventional renal clear cell carcinoma StII (T2aN0M0), tumor size 9.7 in widest dimension, Furhman Nuclear Grade 2. No peritumoral lymphovascular invasion was noted. Ureteral line of resection and renal vessels were negative for tumor involvement (Figure 5).

Hormonal therapy with Tamoxifen was started 12 days after surgery and was referred to radio-oncology service one-month post-operation for 25 sessions of radiotherapy as adjuvant therapy for the breast cancer. Surveillance post nephrectomy for Stage II renal Cancer include baseline abdominal imaging (CT scan/ Magnetic Resonance Imaging) within 3-6 months for at least 3 years then annually up to 5 years. No adjuvant chemotherapy is warranted for the renal cancer in this case. Genetic testing was done revealing a mutation in the ATM gene.



**Figure 4:** Photomicrograph of patient's right breast with axillary tissue post mastectomy (soaked in formalin for 24 hours).



**Figure 5:** Photomicrograph of the patient's left renal mass (11x10.5x7.4cm) post radical nephrectomy.

Guide 1 Invasive breast cancer stages		
Stage 1	Stage 1A	• T1, N0, M0
	Stage 1B	• T0, N1mi, M0 • T1, N1mi, M0
Stage 2	Stage 2A	• T0, N1, M0 • T1, N1, M0 • T2, N0, M0
	Stage 2B	• T2, N1, M0 • T3, N0, M0
Stage 3	Stage 3A	• T0, N2, M0 • T1, N2, M0 • T2, N2, M0 • T3, N1, M0 • T3, N2, M0
	Stage 3B	• T4, N0, M0 • T4, N1, M0 • T4, N2, M0
	Stage 3C	• Any T, N3, M0

NCCN Guidelines for Patients®:  
Invasive Breast Cancer, 2020

11

**Table 1:** Breast Cancer Staging based on National Comprehensive Cancer Network(NCCN) Guidelines.

T = Tumor Size		
	T1	Tumor is 2cm or less
	T1mi	Tumor is micrometastasis of 2 mm or less
	T2	Tumor is 2.1cm to 5 cm
	T3	Tumor is more than 5 cm
	T4	Tumor is of any size and has invaded nearby structures such as the chest wall and skin of the breast
	T4d	Inflammatory carcinoma
N – Regional Lymph Node Spread		
	N0	No cancer in the regional lymph node
	N1, N2, N3	Regional lymph node metastases are found
	N1mi	Micrometastases are found in the lymph nodes
M= Metastasis		
	M0	No distant Metastasis
	M1	Distant metastasis found

**Table 2:** American Joint Committee on Cancer (AJCC), TNM Staging for Kidney Cancer.

T = Primary Tumor		
TX		Primary Tumor cannot be assessed
T0		No evidence of Primary Tumor
T1		Tumor less than or equal to 7cm in greatest dimension, limited to the kidney
	T1a	Tumor less than or equal to 4cm in greatest dimension, limited to the kidney
	T1b	Tumor >4cm but less than or equal to 7cm in greatest dimension, limited to the kidney
T2		Tumor > 7cm in the greatest dimension, limited to the kidney
	T2a	Tumor > 7cm but less than and equal to 10cm in greatest dimension, limited to the kidney
	T2b	Tumor >10cm, limited to the kidney
T3		Tumor extends into major veins or perinephric tissues, but not into the ipsilateral adrenal gland and not beyond Gerota's fascia
	T3a	Tumor extends into the renal vein or its segmental branches, or invades the pelvicalyceal system, or invades perirenal and/or renal sinus fat but not beyond Gerota's fascia
	T3b	Tumor extends into the vena cava below the diaphragm
	T3c	Tumor extends into the vena cava above the diaphragm or invades the wall of the vena cava
T4		Tumor invades beyond Gerota's fascia (including contiguous extension into the ipsilateral adrenal gland)
N = Regional Lymph Nodes		
NX		Regional lymph nodes cannot be assessed
N0		No distant Metastasis
N1		Metastasis in the regional lymph node(s)
M = Distant Metastasis		
M0		No distant Metastasis
M1		Distant Metastasis

**Table 3:** AJCC Prognostic Groups.

	T	N	M
Stage I	T1	N0	M0
Stage II	T2	N0	M0
Stage III	T1-T2	N1	M0
	T3	Nx, N0-N1	M0
Stage IV	T4	Any N	M0
	Any T	Any N	M1



## Discussion

Multiple primary malignancies (MPM) occurring concurrently in the same patient is an established phenomenon. It is defined as two or more malignancies with distinct characteristics occurring in the same or other organ of an individual patient<sup>3</sup>. Prevalence of multiple primary malignancies is about 4.5-11.7%, according to literature review on 1, 104 269 cancer patients<sup>4</sup>. MPM can be divided into synchronous malignancies and metachronous malignancies. Synchronous malignancies are malignant tumors occurring at the same time or within six months of diagnosis of the first tumor. The case reported fits this criteria since the renal mass was diagnosed within 6 months after the diagnosis of breast cancer. Those that do not fit the definition are classified as metachronous malignancies<sup>5</sup>. The widely accepted criteria in diagnosing MPM was established by Warren and Gates. Each tumor must be histopathologically confirmed; each is geographically separated, by normal mucosa, and distinct; and; the probability of one being a metastasis of the other must be omitted<sup>4</sup>. The presented case fulfilled the criteria and is classified as synchronous malignancies. For our patient, Tumors of the digestive system were the most common multiple primary malignant tumors (39.1%), followed by urogenital system and respiratory system tumor<sup>6</sup>.

The co-existence of renal malignancy with synchronous or metachronous tumor of other organs have been reported<sup>7 8 9</sup>, similar to the association of breast cancer with other malignancies<sup>10</sup>. On the other hand, studies and literature discussing synchronous breast and renal cancer have been presented mostly in case reports and small case series due to its rarity. In a report by Arjunan R et al., a 45-year old female came in with complains of abdominal pain and loss of appetite. Examination of the abdomen and pelvis was unremarkable, however, a mass on the right breast and enlarged lymph node were noted on the breast exam. Imaging studies showed a right breast mass. Subsequently, a mass on the right kidney was incidentally identified in the metastatic workup for the breast mass. Right modified radical mastectomy with right radical nephrectomy was done in a single setting. Histopathology reports of the right kidney and breast revealed papillary Renal Cell Carcinoma (RCC) with aggregates of foamy macrophages, Fuhrman nuclear grade III and grade III invasive ductal carcinoma, no special type, respectively<sup>5</sup>. Another case was reported by Üreyen O et. al., a 77-year old menopausal woman who complained of left breast mass with axillary lymphadenopathy. Work up, including ultrasonography, mammography and biopsy of the left breast, revealed invasive ductal carcinoma. The same as the previous case, an incidental finding of a left kidney mass was seen in abdominal computed tomography scan for metastasis workup. In this case, breast conserving surgery and axillary lymph node dissection was performed first, followed by partial nephrectomy 4 weeks later. Histopathology report demonstrated invasive ductal carcinoma and clear cell-renal carcinoma<sup>11</sup>.

In 2005, a study reported a 26% prevalence of synchronous breast cancer with renal cell carcinoma<sup>9</sup>. However, later study by Jiao F et. al reported eight cases of co-existing renal and breast cancer with lower prevalence of 13.1%<sup>3</sup>. In a study conducted by Sas-Korczyńska B et. al., 3 out of 112 breast cancer patients had concurrent renal malignancy<sup>10</sup>.

In literature, the etiology of multiple primary malignant tumors includes genetic predisposition, previous medical treatment (radiotherapy or chemotherapy), environmental factors (tobacco, pollution, occupation,), gender-specific factors, hormonal factors, and interactions of these factors<sup>9</sup>. There were studies implicating the role of hormone-estrogen receptor complex in development of renal cancer. In a study by Di Silverio F et. al., 17 cases of renal cell carcinoma were associated with other primary tumors of steroid hormone target tissues such as breast, endometrium and ovary<sup>12</sup>. Close association of estrogen receptor genes with renal cell carcinoma was established in a study by Liu Z et. al.<sup>13</sup>. As investigated by Tanaka Y et. al., development of renal malignancy and aneuploidy in cells were seen in Syrian hamsters exposed to estrogen<sup>14</sup>. These studies recommend the need for further investigation of the role of endocrine manipulation in renal cell carcinoma that may bridge to the understanding of the occurrence of synchronous breast and renal malignancies such as in our case.

In this case, genetic testing was done revealing a mutation in the ATM gene. The Ataxia-Telangiectasia Mutated (ATM) gene is an oncosuppressor found in chromosome 11q23. The ATM protein encoded by the gene is involved in DNA repair and activates DNA damage pathways<sup>15</sup>. In general, the ATM gene is dysregulated in a wide range of malignancies. The greatest prevalence include lung adenocarcinoma, colon adenocarcinoma, endometrial endometrioid adenocarcinoma, prostate adenocarcinoma, and bladder urothelial carcinoma. Other malignancies include breast, pancreatic, gastric, renal, and skin cancers<sup>16</sup>.

In this case, genetic testing was done revealing a mutation in the ATM gene. The Ataxia-Telangiectasia Mutated (ATM) gene is an oncosuppressor found in chromosome 11q23. The ATM protein encoded by the gene is involved in DNA repair and activates DNA damage pathways<sup>15</sup>. In general, the ATM gene is dysregulated in a wide range of malignancies. The greatest prevalence include lung adenocarcinoma, colon adenocarcinoma, endometrial endometrioid adenocarcinoma, prostate adenocarcinoma, and bladder urothelial carcinoma. Other malignancies include breast, pancreatic, gastric, renal, and skin cancers<sup>16</sup>.

## Conclusion

Patients diagnosed with any malignancy, may it be malignancy of the breast, kidney or other organs, should be properly worked up at the onset. The discovery of multiple primary malignancies, with any etiology, emphasizes the importance of holistic approach to cancer patients. Synchronous malignancies may be treated simultaneously with curative intent. However, in cases that simultaneous treatment cannot be done, the more aggressive malignancy should be addressed first. In the case of this patient, a synchronous renal malignancy was diagnosed during metastatic work-up for her breast cancer. After full course sequential neoadjuvant chemotherapy showed partial response to treatment, total mastectomy with ALND and radical nephrectomy was done with no complications. Postoperatively, patient was managed accordingly with hormonal therapy, radiation therapy, and surveillance for recurrence of the renal cell carcinoma.

## Conflict of Interest

The authors declare no conflict of interest.

## References

1. Zhang L, Feng L, Cong H, et al. Multiple primary malignant neoplasms: A case report and literature review. *Oncol Lett.* 2019;18(4):4210-4220. doi:10.3892/ol.2019.10779
2. Laudico A V, Mirasol-lumague MR, Mapua CA. 2015 PHILIPPINE CANCER FACTS and ESTIMATES. Published online 2015.
3. Jiao F, Yao LJ, Zhou J, Hu H, Wang LW. Clinical features of multiple primary malignancies: A retrospective analysis of 72 Chinese patients. *Asian Pacific J Cancer Prev.* 2014;15(1):331-334. doi:10.7314/APJCP.2014.15.1.331
4. Irimie A, Achimas-Cadariu P, Burz C, Puscas E. Multiple primary malignancies -Epidemiological analysis at a single tertiary institution. *J Gastrointest Liver Dis.* 2010;19(1):69-73.
5. Arjunan R, Kumar D, Veerendra Kumar K V., Premlatha CS. Breast cancer with synchronous renal cell carcinoma: A rare presentation. *J Clin Diagnostic Res.* 2016;10(10):XD03-XD05. doi:10.7860/JCDR/2016/20362.8683
6. Lv M, Zhang X, Shen Y, et al. Clinical analysis and prognosis of synchronous and metachronous multiple primary malignant tumors. *Med (United States).* 2017;96(17).doi:10.1097/MD.0000000000006799
7. JC S, N R, T R, F L, P M, H M. Synchronous bilateral renal cell carcinoma and prostate cancer: A bad luck case with a good outcome. *Clin Case Reports Rev.* 2015;1(8):165-166. doi:10.15761/ccrr.1000155
8. Dafashy TJ, Ghaffary CK, Keyes KT, Sonstein J. Synchronous Renal Cell Carcinoma and Gastrointestinal Malignancies. *Case Rep Urol.* 2016;2016(Case 2):1-5. doi:10.1155/2016/7329463
9. Beisland C, Talleraas O, Bakke A, Norstein J. Multiple primary malignancies in patients with renal cell carcinoma: A national population-based cohort study. *BJU Int.* 2006;97(4):698-702. doi:10.1111/j.1464-410X.2006.06004.x
10. Sas-Korczyńska B, Mituś JW, Kamzol W, Rzepa MK, Jakubowicz J, Wysocki WM. Synchronous malignancies in patients with breast cancer. *Nowotwory.* 2017;67(6):336-341. doi:10.5603/NJO.2017.0055
11. Üreyen O, Dadali E, Akdeniz F, et al. Co-existent breast and renal cancer. *Turkish J Surg.* 2015;31(4):238-240. doi:10.5152/UCD.2015.2874
12. Di Silverio F, Sciarra A, Flammia GP, Mariani M, De Vico A. Multiple primary tumors: 17 cases of renal-cell carcinoma associated with primary tumors involving different steroid-hormone target tissues. *World J Urol.* 1997;15(3):203-209. doi:10.1007/BF02201858

13. Lu Y, Liu Z, Lu Y, He Z, Chen L. Expression analysis of the estrogen receptor targetgenes in renal cell carcinoma. *Mol Med Rep.* 2015;11(1):75-82. doi:10.3892/mmr.2014.2766
14. Tanaka Y, Sasaki M, Kaneuchi M, Fujimoto S, Dahiya R. Estrogen receptor alphapolymorphisms and renal cell carcinoma--a possible risk. *Mol Cell Endocrinol.* 2003;202(1-2):109-116. doi:10.1016/s0303-7207(03)00071-6
15. Stucci L, Interno, V. , et.al. The ATM Gene in Breast Cancer: Its Relevance in ClinicalPractice. *MDPI Journal.* 2021 12 (5), 727. doi: 10.3390/genes12050727
16. ATM Mutation - My Cancer Genome. Vanderbilt-Ingram Cancer Center, 2017, <https://www.mycancergenome.org/content/alteration/atm-mutation/>

**Citation:** T. Castillon MN, Dayot DM, Claparols MF, Vinco JS, Cabaya N. Double Trouble: A Case of Synchronous Breast and Renal Malignancies Associated with ATM Gene Mutation in a 41-Year-Old Filipino Female. *SVOA Medical Research* 2024, 2:2, 40-47. doi: 10.58624/SVOAMR.2024.02.016

**Copyright:** © 2024 All rights reserved by T. Castillon MN., et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.